All ExchangesFibroGen Stock Signals
Latest Data & Signals Issued
| Signal Type | Signal Value | Data | |
|---|---|---|---|
| Score | -4.062 | 66 days ( 94.77 % ) | |
| Last Price | $0.87 | 10.50 % | |
| High/ Low | $0.780 - $0.92 | 0.99% | |
| Chg 7 Days | -5.58 % | $0.93 $0.87 | |
| Chg 30 Days | -30.59 % | $1.26 $0.87 | |
| Chg 12 mos | -92.87 % | $12.27 $0.87 | |
| Trend - 3 mos | -35.03 % | Width: 752.21 % | |
| Trend - 12 mos | -49.67 % | Width: 2243.28 % | |
| Pred. range - 3 mos | N/A - $7.18 | -100.00 % - 721.05 % | |
| Pred. range - 12 mos | $0.336 - $7.86 | -61.63 % - 799.01 % | |
| Short mv avg 3 mos | Buy | 2023-09-07 - 10 days | |
| Long mv avg 3 mos | Sell | 0000-00-00 - N/A days | |
| Short/Long mv avg 3 mos | Sell | 0000-00-00 - N/A days | |
| Short mv avg 12 mos | Buy | 2023-06-12 - 70 days | |
| Long mv avg 12 mos | Sell | 2023-04-21 - 105 days | |
| Short/Long mv avg 12 mos | Sell | 2023-04-13 - 111 days | |
| Pivot Short | Buy | 2023-09-18 - 3 days | |
| Bollinger | Buy | 2023-06-26 - 61 days | |
| MACD | Buy | No Dates Stored For This Signal |
Signals Effectiveness
Backtesting is not only a way to check stock signal accuracy, but also a tool to continually improvement. Data can be used for self adjustment as each stock has an individual behavior.
Accuracy and return is not the same. A stock signal may provide low statistical accuracy, but the signals may prove high return in average.
Sharp market dips or fundamental changes (earning reports, news updates etc), may force a short term reaction and disturb the signals (Signals may jump quickly from buy to sell, just to return to buy).
Stock Score
Bollinger Bands
MACD
Moving Average (7d)
About FibroGen
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China ... FGEN Profile
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
